about
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemiaMHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersPrediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data MininRituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.High-hyperdiploidy in Philadelphia positive adult acute lymphoblastic leukaemia: case-series and review of literature.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Biology and management of relapsed acute myeloid leukaemia.Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTAdoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersTolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA TrialMemory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation eventAssociation of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.Molecularly targeted therapy in myeloid leukaemias.Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms.Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionA comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.Embracing model-based designs for dose-finding trials.Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia.Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of theGreatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
P50
Q27653882-480C8BD7-B52B-42C4-BA81-EAA01765AEC1Q28083485-46788FFC-4F95-494E-BCF6-101169B8C66DQ30412320-C4D370D0-B2A5-4DD1-A4A0-BC53E5993085Q30570744-BDDBC026-EAC9-4D68-8646-4449DE8AF859Q30984889-A4632177-F7E1-43C9-BE29-4CA20F67AAD9Q33363871-ED349618-277B-44A6-96FA-7E9170FF95F6Q33383056-7C26CADC-4D98-4899-94D2-AC69943C5582Q33886217-32ADB6A0-941C-4DC8-B425-3CB21C1ABC38Q34095668-995C99A4-EEE6-4661-93D7-CC2C686BE34DQ34325179-2FC47FB5-FF6B-4EA2-8D41-A7FF1AA27DD0Q34424018-B7D17230-96C7-4EFC-9E1F-92E88FB58ED8Q34617770-6073687C-1DB7-4B94-837F-79FA1D90433DQ35122191-9326262B-7A0D-44B4-92C4-08EC4982D076Q35146312-110D70CE-A9B1-4665-8465-D37EA4FC085BQ35348105-6B69EAC8-2D22-436F-A5E8-AC6F999E429DQ35821259-73F3A54A-3E5F-472D-BF68-E5805AA401C0Q36085026-D3FC1081-C741-4A02-88FC-4ECC582AAA78Q36121885-992B1DE6-3313-4D32-A0C8-7625031E2719Q36403280-53AF4A5B-4008-4CC3-A23D-E6C3C757645DQ36506169-86FC69EB-E013-449F-9328-74F3D4165B92Q36519976-39ECB11C-CF2C-4124-A17A-F17587D5F3A4Q36673472-02A6F762-F97A-49F4-9944-6420C3D6F4ABQ37056550-5C02E5D5-191C-4FBC-BB47-2F259B267EBEQ37179007-2BB04968-8FB8-4B07-BEEF-EF543E9659E3Q37216476-6349E98C-7C4B-4EA0-8188-24AC12DDC779Q37367237-CB9D5273-5592-4E6D-99BC-AB64E9515521Q37369934-C28FE282-F3FC-41F1-B23B-3AFF3847A1AFQ37595693-F13E7ED6-617F-49FA-9F77-913D974D446EQ37683539-85DC1FCC-6885-45D3-AA6B-44D6C3D98771Q38256888-CD844E07-C943-4D6A-B47C-DE79D921493DQ38276066-37444BBF-B8DA-4AC8-B8AB-28DE50125D7EQ38636111-FD7CFE53-9A6A-4B08-A61A-0F18D90FEB22Q38700689-0CDDCCAA-0AE2-41AD-A290-8FE713914105Q39209778-D1BD47B5-12B2-4130-9C03-87E787FAF752Q39475017-AD8FC894-630B-4562-AF97-178DE31EBD7FQ39617678-8CD18047-DC4E-404D-835D-720F29442A14Q39695762-062C5559-E93A-4D73-98C4-9124F4C8BF61Q39708265-5AD48734-CB74-4F29-9161-51CA7CAC04FAQ39978862-54EF26BE-7B83-43B6-99D1-6D6F4978495EQ40229220-BB2B63D6-8DDA-4502-893A-17670E09CA54
P50
description
researcher ORCID ID = 0000-0001-5041-6678
@en
wetenschapper
@nl
name
Charles Craddock
@ast
Charles Craddock
@en
Charles Craddock
@es
Charles Craddock
@nl
type
label
Charles Craddock
@ast
Charles Craddock
@en
Charles Craddock
@es
Charles Craddock
@nl
prefLabel
Charles Craddock
@ast
Charles Craddock
@en
Charles Craddock
@es
Charles Craddock
@nl
P31
P496
0000-0001-5041-6678